Braeburn Pharmaceuticals, Inc. – IPO: ‘S-1/A’ on 1/18/17 – ‘EX-3.2’ On: Wednesday, 1/18/17, at 7:49am ET · Accession #: 1047469-17-227 · File #: 333-215398 As Of Filer Filing For·On·As Docs:Size Issuer Agent 1/18/17 Braeburn Pharmaceuticals, Inc. S-1/A 7:4.6M Merrill Corp/New/FA

2017-02-02

Braeburn Pharmaceuticals wants to raise $150 million in an IPO at a proposed market cap of $600 million. The company is commercializing an implantable delivery device for treatment of opioid Feb 2 (Reuters) - Braeburn Pharmaceuticals Inc, the maker of the first long-acting implant to treat opioid addiction in the United States, said on Thursday that it had decided to withdraw its Braeburn Pharmaceuticals has registered an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). Braeburn Pharmaceuticals files plans for $150m IPO. Braeburn Pharmaceuticals filed plans for a $150 million initial public offering last week with the Securities & Exchange Commission, leaving out any specific pricing details. BRIEF-Braeburn Pharmaceuticals says it and Apple Tree Partners are not proceeding with an IPO Braeburn Pharmaceuticals Shelves IPO Plans Biotech offerings are off to an uneven start in 2017 Braeburn Pharmaceuticals has filed with the SEC for a $150 million public offering. Along with Titan Pharmaceuticals (NASDAQ: TTNP), the biopharma is the developer of an implant that treats addiction to prescription painkillers, heroin and other opioids.

Braeburn pharmaceuticals ipo

This page includes all May 27, 2016 Apple Tree Partners's more than $100 million bet on Braeburn Pharmaceuticals Inc. could pay off now that Braeburn has won regulatory Feb 2, 2017 Inc. staging successful offerings and Braeburn Pharmaceuticals Inc. saying Thursday that it won't go forward with a planned IPO at this time. Dec 30, 2016 Braeburn Pharmaceuticals Inc filed with U.S. regulators on Friday to raise up to $150 million in an initial public offering, seven months after its Braeburn Inc. SEC Registration picture. Braeburn Pharmaceuticals Completes $110M Mezzanine Round of Prof Bruce — Waterfront Lots on Madawaska River jobs with Braeburn to view and apply for now with BioSpace. Braeburn Inc. announces the publication of its 48-week, open-label, multi-center, global Dr. Malamut brings to Braeburn more than 25 years of pharmaceutical and clinical& Braeburn is dedicated to delivering solutions for people living with the serious, often Also Known As Braeburn Pharmaceuticals; Legal Name Braeburn Inc. Braeburn is committed to the fight against opioid addiction, or opioid use disorder (OUD). Learn more about Braeburn here at the official corporate site. Braeburn Pharmaceuticals Inc., Princeton, New Jersey (October 2015 – October 2016). Venture Capital backed commercial-stage specialty pharmaceutical Mar 30, 2020 The development and commercialization rights to Probuphine for the U.S. and Canada were originally licensed to Braeburn Pharmaceuticals, Dec 5, 2020 BRIEF-Braeburn Pharmaceuticals sees IPO of 7.7 mln shares priced between $18-$21 per share 18th Jan '17 News Discover the metrics that Camurus and Braeburn Pharmaceuticals Announce Topline Phase 2 Results Exercise of the over-allotment option in the initial public offering of Camurus Anonymous board for Braeburn Pharmaceuticals.

Braeburn Pharmaceuticals, Inc.(NASDAQ:BBRX)创立于2012年9月，是一家特拉华州公司，总部位于美国新泽西州Princeton，全职雇员97人(1/1/2017)，是一家

Other investors included Avista Capital Partners, RA Capital Management, Deerfield Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA developing proprietary therapeutics primarily for the treatment of central nervous system ("CNS") disorders. In September 2018, Titan Pharmaceuticals underwent an IPO wherein it raised $9.5 million in gross proceeds.

Plymouth Meeting, Pa. —September 15, 2020—Braeburn announces that it has appointed Brian Hirsch as General Counsel and Corporate Secretary. Mr. Hirsch joins Braeburn with more than 20 years of pharmaceutical and legal experience, handling complex legal matters for both branded and generic biopharmaceutical companies.

Braeburn Pharmaceuticals, a commercial stage pharmaceutical offering implantable treatment for opioid addiction, filed on Friday with the SEC to raise up to $150 million in an initial public offering. 2017-02-02 · Braeburn Pharmaceuticals Inc. (Princeton, N.J.) said Thursday it has decided against conducting an IPO, citing Read the full 155 word article The Princeton, New Jersey based Braeburn Pharmaceuticals, Inc. has filed with the U.S. Securities and Exchange Commission for an initial public offering of up to $150 million shares of common stock. Braeburn Pharmaceuticals won't continue with an initial public offering, the company and its only shareholder, Apple Tree Partners, said, though they may consider an IPO in the future. The pharmaceuticals company, which shelved plans to go public nearly a year ago, just raised $110 million in mezzanine financing led by Wellington Capital Management.
Bk 2 stockholm

Braeburn Pharmaceuticals pulled its plans for a $150 million initial public offering yesterday, citing unstable market conditions. The Princeton, N.J.-based company 1st announced plans to go public in late December and in mid-January, Braeburn said it planned to raise $150 million by Braeburn is committed to the fight against opioid use disorder.

Titan Pharmaceuticals, Inc. is a biopharmaceutical company based in San Francisco, CA or chronic pain. FDA Approval was granted on 26 May 2016. It was licensed to Braeburn Pharmaceuticals for marketing and commercialization. NextCure in connection with its formation, US$67m Series A financing, IPO, and Braeburn Pharmaceuticals on its US$110m mezzanine round of financing led 12 Dec 2018 VC firm that invests in pharmaceuticals, biotech, medtech, and healthcare Gloucester Pharmaceuticals.
Revision plan eli review

Braeburn Pharmaceuticals Inc., a New Jersey biotech that just launched an estimated $150 million initial public offering to help fund a drug treating opioid addiction, suspended plans Thursday

The company is commercializing an implantable delivery device for treatment of opioid Braeburn Pharmaceuticals has registered an S-1 form with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO). Braeburn Pharmaceuticals wants to raise $150 in an IPO. The company is commercializing an improved delivery system treatment for opioid addiction. The system has been recently approved for * Braeburn Pharmaceuticals Inc - J.P. Morgan, BofA Merrill Lynch, Deutsche Bank securities are underwriters to IPO * Braeburn Pharmaceuticals Inc - Apple Tree Partners IV LP to buy $40 million of Braeburn Pharmaceuticals has filed for a $150 million IPO. The listing is intended to give Braeburn the financial clout to commercialize its six-month opioid addiction implant that won FDA approval Braeburn pulls the plug on $150m IPO, citing market conditions February 3, 2017 By Sarah Faulkner Braeburn Pharmaceuticals pulled its plans for a $150 million initial public offering yesterday, citing unstable market conditions. Opioid addiction, also known as opioid use disorder (OUD), is a medical condition requiring medical treatment. Together with counseling and support, Braeburn’s next generation medicines are developed with an aim to support patients with OUD as they focus on the reintegration of their lives and communities. Braeburn Pharmaceuticals has filed for a $150 million IPO. The listing is intended to give Braeburn the financial clout to commercialize its six-month opioid addiction implant that won FDA approval (Reuters) - Braeburn Pharmaceuticals Inc, the maker of the first long-acting implant to treat opioid addiction in the United States, said on Thursday that it had decided not to proceed with its initial public offering, citing current market environment. The company, which filed to go public in late December, was expected to offer about 7.7 million shares in the price range of $18-$21 per share Braeburn pulls the plug on $150m IPO, citing market conditions February 3, 2017 By Sarah Faulkner Braeburn Pharmaceuticals pulled its plans for a $150 million initial public offering yesterday, citing unstable market conditions.

Braeburn Pharmaceuticals, Inc.(NASDAQ:BBRX)创立于2012年9月，是一家特拉 华州公司，总部位于美国新泽西州Princeton，全职雇员97人(1/1/2017)，是一家

Braeburn Pharmaceuticals Inc., a New Jersey biotech that just launched an estimated $150 million initial public offering to help fund a drug treating opioid addiction, suspended plans Thursday

Braeburn Pharmaceuticals, Inc.(NASDAQ:BBRX)创立于2012年9月，是一家特拉华州公司，总部位于美国新泽西州Princeton，全职雇员97人(1/1/2017)，是一家